Mitoxantrone Plus Gemcitabine in Pretreated Patients with Metastatic Breast Cancer

References

• Greenlee RT, Murray T, Bolden S. Cancer statistics. Cancer J Clin 2000; 50: 7–33.
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J. Salvage chemotherapy for metastatic breast cancer. Cancer Control 1999; 6 (2): 22–27
   PubMedGoogle Scholar
• Norton L, Simon R. The Norton-Simon hypothesis revis-ited. Cancer Treat Rep 1986; 70: 163–9.
   PubMedGoogle Scholar
• Silvestris N, D'Aprile M, Andreola G, et al. Rationale for the use of gemcitabine in breast cancer (Review). Int J Oncol 2004; 24: 389–98.
   PubMed Web of Science ®Google Scholar
• Smith IE, Stuart-Harris R, Pavlidis N, et al. Mitoxantrone article (Novantrone) as single agent and in combination chemothera-py in the treatment of advanced breast cancer. Cancer Treat Rev 1983; 10: 37–40.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Williams MR, Todd JH, et al. Mitoxantrone is a useful palliative therapy in advanced breast cancer. Am J Clin Oncol 1989; 12: 393–6.
   PubMed Web of Science ®Google Scholar
• Brufman G, Haim N, Ben-Baruch N, et al. Second-line chemotherapy with mitoxantrone as a single agent in metasta-tic breast cancer. J Chemother 1993; 5: 43–6
   PubMed Web of Science ®Google Scholar
• Susnjar S, Vasovic S, Neskovic-Kostantinovic Z, et al. Mitoxantrone, 5-fluorouracil and low-dose leucovorin in dox-orubicin-resistant advanced breast cancer patients: a phase II study. Tumori 1999; 85: 478–82.
   PubMed Web of Science ®Google Scholar
• Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731–6.
   PubMed Web of Science ®Google Scholar
• Blackstein M, Vogel CL, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer. The European Cancer Conference, Hamburg, 14-18 September. Eur J Cancer 1997; 33 (Suppl 8):5149.
   Google Scholar
• Spielmann M, KaIla S, Llombart-Cussac A, et al. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containing regi-mens. Eur J Cancer 1997;33 (Suppl 8):5149.
   Google Scholar
• Seihman AD. Monotherapy options in the management of metastatic breast cancer. Oncol. 2003; 30 (suppl 3): 6-10.
   Google Scholar
• Rha SY, Jueng H, Kim Y, et al. Efficacy of gemcitabine as salvage treatment in breast cancer patients refractory to anthracycline and paclitaxel based regimen. Proc Am Soc Clin Oncol 2002; 21:576.
   Google Scholar
• Valerio MR, Cicero G, Armata MG et al. Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol 2001; 20:51b.
   Google Scholar
• Schmid P, Akrivakis K, Flath B et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 1999; 10: 625–31.
   Google Scholar
• Blockstein M, Vopal Cl, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer. A phase II trial. Oncology 2002; 62: 2–8.
   Google Scholar
• Perez-Manga G, Lluch A, Alba E, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 2000; 18: 2545–52.
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multi-center phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 1999; 10: 211–5.
   Google Scholar
• Nicolaides C, Dimopoulos MA, Samantas E, et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by Hellenic Cooperative Oncology Group. Ann Oncol 2000; 11: 873–5.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Nag S, Colderillo-Ruiz G et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pretreated metastatic breast cancer (MBC): Interim results of a global phase III study. Proc Am Soc Clin Oncol 2003; 22:7.
   Google Scholar
• Rivena E, Valero V, Arun B, et al. Phase II study of pegilated liposomal doxorubicin in combination with gemc-itabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21: 3249–3254.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Nikolaides C, Bafaloukos D et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000; 18: 503–509.
   Google Scholar
• Sanchez-Roviro P, Jaen A, Gonzales E, et al. Phase II trial of gemcitabine / doxorubicine / paclitaxel administered every other week in patients with metastatic breast cancer. Clin Breast Cancer 2000; 1: 226–232.
   PubMedGoogle Scholar
• Lorusso V, Catino A, Mancarella S, et al. Phase I/II study of gemcitabine plus mitoxantrone in advanced breast cancer. ECCO 1999; 10: 1274.
   Google Scholar
• Lorusso V, Catino A, Mancarella S, et al. Phase I study of gemcitabine plus mitoxantrone in advanced breast cancer. Proc Am Soc Clin Oncol 1999; 18: 1140.
   Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Lentner C. Geigy Scientific Tables (Exact Confidence Limits for p'); Ciba-Geigy: Switzerland, 1982, pp 89-102.
   Google Scholar
• Lorusso V, Crucitta E, Silvestris N, et al. Phase I/II study of gemcitabine plus mitoxantrone as salvage chemother-apy in metastatic breast cancer. Br J Cancer 2003; 88: 491–495.
   PubMed Web of Science ®Google Scholar
• Heinemann V: Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003; 64: 191–206.
   Google Scholar
• Smorenburg C, Poontebal M, Seynaeve C et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both anthracycline and a tax-ane breast cancer. Res Treat 2001; 66: 83–87.
   Google Scholar
• Peacock NW, Burris HA, Dieras V, et al. Phase I trial of vinorelbine with mitoxantrone in patients with refractory solid tumors. Invest New Drugs 1998; 16 (1): 37–43.
   PubMed Web of Science ®Google Scholar
• Laufman LR, Spiridonidis CH, Pritchard et al. Monthly docexatel and weekly gemcitabine in metastatic breast cancer: A phase II trial. Ann Oncol. 2001; 12 (9): 1259–1264.
   Google Scholar
• Heinsworth JD, Calvert S, Greco FA. Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2002; 20 (7-8) :863–871.
   PubMed Web of Science ®Google Scholar
• Pelegri A, Calvo L, Florian J, et al. Every-other-week combination of gemcitabine and docetaxel as first-line therapy in advanced breast cancer patients. Preliminary results from a phase II trial. Breast Cancer Res Treat 2001; 69 (3) (abstract 3560).
   Google Scholar